Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1117 | 1023 | 1191 | 1263 | 1523 | 1993 |
Fund Return | 11.7% | 2.32% | 19.11% | 8.08% | 8.78% | 7.14% |
Place in category | 874 | 899 | 793 | 334 | 358 | 213 |
% in Category | 38 | 38 | 36 | 19 | 21 | 18 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Cleome Index USA Equities Y EUR Acc | 2.81B | 18.87 | 10.40 | 12.88 | ||
Cleome Index USA Equities Z EUR Acc | 2.81B | 20.09 | 11.92 | 14.12 | ||
LU2197358042 | 2.81B | 20.02 | 11.83 | - | ||
Cleome Index USA Equities R EUR Acc | 2.81B | 19.82 | 11.59 | 13.71 | ||
LU1434523954 | 2.16B | 15.21 | -6.23 | 4.64 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
European Growth Fund A Acc EUR | 157.47M | 15.19 | 6.23 | 5.66 | ||
European Growth Fund E Acc EUR | 20.7M | 14.50 | 5.44 | 4.87 | ||
European Growth Fund Y Acc EUR | 142.92M | 15.85 | 7.14 | 6.53 | ||
European Growth Fund Y DIST EUR | 65.06M | 15.91 | 7.15 | 6.54 | ||
European Growth Fund A DIST Eue | 6.49B | 15.15 | 6.24 | 5.66 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 3.98 | 768.9 | +0.76% | |
ASML Holding | NL0010273215 | 3.15 | 627.10 | +0.95% | |
Nestle | CH0038863350 | 2.54 | 82.72 | +1.40% | |
AstraZeneca | GB0009895292 | 2.40 | 11,022.0 | -0.18% | |
Roche Holding Participation | CH0012032048 | 2.12 | 273.10 | +1.94% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Buy | Strong Buy |
Technical Indicators | Sell | Strong Buy | Strong Buy |
Summary | Sell | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review